-
20 drugs/vaccines approved by the State Food and Drug Administration in the first half of 2021
Time of Update: 2021-08-10
This variety is China's first approved small molecule inhibitor specifically targeting MET kinase, and its listing provides a new treatment option for patients with advanced non-small cell lung cancer with MET 14 exon skipping .
-
Haisco submits a marketing application for the fourth indication of cyclopofol injection
Time of Update: 2021-08-10
On June 30, Haisco issued an announcement stating that its innovative drug cyclopofol injection for the indication of "general anesthesia induction and maintenance" has been recently accepted by the Drug Evaluation Center of the China National Medical Products Administration .
-
Hengrui Medicine: HR17031 injection obtained the qualification of US FDA clinical trial
Time of Update: 2021-08-10
On July 1, Hengrui Pharmaceutical announced that the drug HR17031 injection has obtained the clinical trial qualification of the US FDA and is intended to be used for the treatment of type 2 diabetes .
S. dollars, and the global sales of Soliqua 100/33 will be approximately 184 million U.
-
Accelerate the development of mRNA vaccines Sanofi plans to develop 6 clinical-phase candidate products within 4 years
Time of Update: 2021-08-10
On June 29, 2021, Sanofi announced that it will invest approximately 400 million euros a year to establish the first mRNA vaccine center of excellence (Center of Excellence) .
Note: The original text has been deletedReference materials:[1] Sanofi launches dedicated vaccines mRNA Center of Excellence.
-
Resistance mutation mechanism of KRAS G12C inhibitor
Time of Update: 2021-08-10
On June 24, in a study on the mechanism of KRAS G12C acquired drug resistance published in the New England Journal of Medicine, researchers at the Dana-Farber Cancer Institute revealed multiple mechanisms by which cancer cells develop drug resistance .
-
You can see the popularity of the "magic medicine" Pien Tze Huang, and see the plight of proprietary Chinese medicine behind the virtual fire
Time of Update: 2021-08-10
However, when we re-examine the Chinese medicine companies represented by Zhangzhou Pien Tze Huang, this problem seems to be more prominent.
For Chinese patent medicines, centralized procurement puts even more pressure on Chinese medicine companies, and the core of the pressure is price .
-
JAK inhibitor is blocked again!
Time of Update: 2021-08-10
Pfizer's JAK inhibitor Xeljanz, in a post-marketing study for patients with rheumatoid arthritis, discovered dangerous cardiac side effects and additional risks of cancer, which caused the FDA to raise safety concerns about JAK inhibitor drugs .
-
Roche's new intraocular drug delivery system ranibizumab PDS enters priority review in the United States
Time of Update: 2021-08-10
If approved, PDS will be the first and only intraocular implant that can deliver drugs continuously, and will provide an alternative to frequent intraocular injections of anti-vascularity for patients with wet AMD The treatment of endothelial growth factor (VEGF), which is currently the standard care plan for wet AMD .
-
National Food and Drug Administration: Transcatheter aortic valve system approved for marketing
Time of Update: 2021-08-10
National Machinery Note 20203130445 80 Cardiovascular optical coherence tomography equipment and accessories Shenzhen Zhongke Microlight Medical Device Technology Co.
National Machinery Note 20203130445 80 Cardiovascular optical coherence tomography equipment and accessories Shenzhen Zhongke Microlight Medical Device Technology Co.
-
GSK China's pharmaceutical business license cancellation high-value business spin-off MNC "slimming" tide is coming?
Time of Update: 2021-08-10
Following Bristol-Myers Squibb, GlaxoSmithKline (GSK) also announced the cancellation of the drug business license of its subsidiary in China .
8 billion to raise funds for the acquisition of TESARO project investment; secondly, GSK and Pfizer will merge their consumer healthcare businesses Establish a joint venture company .
-
Simcere introduces 2 Alzheimer's disease drug candidates
Time of Update: 2021-08-10
They are the N3pE-targeted oral small molecule glutamyl peptide cyclotransferase in clinical phase 2b ( QPCT) inhibitor varoglutamstat (PQ912), and the monoclonal N3pE antibody PBD-C06 in the preclinical research stage .
-
Xinlitai Erlotinib Hydrochloride Tablets Enters the Administrative Approval Stage
Time of Update: 2021-08-10
com, the total sales of erlotinib in China's public medical institutions and physical pharmacies in Chinese cities will exceed 300 million yuan in 2020 .
-
How to divide the “ten billion cake” of the fourth domestically-made bevacizumab biosimilar drug approved?
Time of Update: 2021-08-10
On June 22, Hengrui Medicine's bevacizumab biosimilar was approved in China for the indications of metastatic colorectal cancer and advanced, metastatic or recurrent non-small cell lung cancer .
-
EGFR inhibitor development home: target degradation
Time of Update: 2021-08-10
Generations of EGFR-TKIs have brought us unlimited imagination, but cancer cells will always come back due to mutations and drug resistance .
-
Tianyao's methylprednisolone sodium succinate for injection passed the consistency evaluation
Time of Update: 2021-08-10
("Jinyao Pharmaceutical") received approval and issuance from the State Food and Drug Administration regarding methylprednisolone sodium succinate for injection (40mg).
-
Biopharmaceutical collection is coming soon
Time of Update: 2021-08-10
On January 29, at a regular policy briefing held by the Information Office of the State Council, Chen Jinfu, deputy director of the National Medical Insurance Administration, said: Biosimilar drugs, including large varieties of proprietary Chinese medicines, are included in the centralized procurement.
-
Foresite, Gilead and others acquire new crown antiviral drugs in a $250 million SPAC transaction
Time of Update: 2021-08-10
On June 29, according to foreign media reports, Foreste Capital announced that it would use one of its SPACs (special purpose mergers and acquisitions company) to list Pardes Biosciences, which was established only last year .
-
GlaxoSmithKline cancels its "Pharmaceutical Business License" in China
Time of Update: 2021-08-10
FinishingrainbowYesterday (June 28), Shanxi Pharmaceutical Equipment Centralized Bidding and Purchasing Network issued a notice showing that the "Drug Business License" of GlaxoSmithKline (China) Investment Co.
It is understood that on June 23, GSK announced the split of its consumer healthcare business merged with Pfizer and established "New GlaxoSmithKline" .
-
Tosunshine: Atorvastatin calcium tablets, a holding subsidiary, obtained a drug registration certificate
Time of Update: 2021-08-10
Atorvastatin calcium is a selective and competitive inhibitor of HMG-CoA reductase.
It reduces plasma cholesterol and lipoprotein levels by inhibiting the synthesis of HMG-CoA reductase and cholesterol in the liver, and increases the surface of liver cells.
-
The fifth batch of countries organized the centralized procurement of medicines to produce the results of the proposed selection
Time of Update: 2021-08-10
Since the establishment of the National Medical Insurance Bureau, it has carried out 5 batches of centralized drug procurement, covering 218 varieties, and involving a market capacity of 220 billion yuan .
